Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients-Reference-Cited by-全球学者库

Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients

Published:2015-03-16 Issue:4 Volume:30 Page:748-755
ISSN:0815-9319
Container-title:Journal of Gastroenterology and Hepatology
language:en
Short-container-title:J Gastroenterol Hepatol

Author:

Liang Xieer¹,Cheng Jun²,Sun Yongtao³,Chen Xinyue⁴,Li Tong⁵,Wang Hao⁶,Jiang Jianning⁷,Chen Xiaoping⁸,Long Hui⁹,Tang Hong¹⁰,Yu Yanyan¹¹,Sheng Jifang¹²,Chen Shijun¹³,Niu Junqi¹⁴,Ren Hong¹⁵,Shi Junping¹⁶,Dou Xiaoguang¹⁷,Wan Mobin¹⁸,Jiang Jiaji¹⁹,Xie Qing²⁰,Shi Guangfeng²¹,Ning Qin²²,Chen Chengwei²³,Tan Deming²⁴,Ma Hong²⁵,Sun Jian¹,Jia Jidong²⁵,Zhuang Hui⁵,Hou Jinlin¹

Affiliation:

1. State Key Laboratory of Organ Failure Research; Guangdong Provincial Key Laboratory of Viral Hepatitis Research; Department of Infectious Diseases; Nanfang Hospital, Southern Medical University; Guangzhou China

2. Beijing Ditan Hospital; Capital Medical University; Beijing China

3. Department of Infectious Diseases; Tangdu Hospital, The Fourth Military Medical University; Xi'an China

4. Beijing Youan Hospital; Capital Medical University; Beijing China

5. Department of Microbiology and Infectious Disease Center; Peking University Health Science Center; Beijing China

6. Hepatology Unit; Peking University People's Hospital; Beijing China

7. Department of Infectious Diseases; The First Affiliated Hospital of Guangxi Medical University; Nanning China

8. Department of Infectious Diseases; Guangdong General Hospital; Guangzhou China

9. Department of Infectious Diseases; The First People Hospital of Foshan; Foshan China

10. Center of Infectious Diseases; West China Hospital of Sichuan University; Chengdu China

11. Department of Infectious Diseases; First Hospital of Peking University; Beijing China

12. Department of Infectious Diseases; Zhejiang University 1st Affiliated Hospital; Hangzhou China

13. Jinan Infectious Diseases Hospital; Ji'nan China

14. Hepatology Unit; No. 1 Hospital Affiliated to Jilin University; Changchun China

15. Department of Infectious Diseases; Second Affiliated Hospital, Chongqing Medical University; Chongqing China

16. The 6th People's Hospital; Hangzhou China

17. Department of Infectious Diseases; Shengjing Hospital of China Medical University; Shenyang China

18. Department of Infectious Diseases; Changhai Hospital, The Second Military Medical University; Shanghai China

19. Liver Center; First Affiliated Hospital of Fujian Medical University; Fuzhou China

20. Department of Infectious Diseases; Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai China

21. Department of Infectious Diseases; Huashan Hospital, Fudan University; Shanghai China

22. Department of Infectious Diseases; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Wuhan China

23. Department of Infectious Diseases; 85th People's Liberation Army Hospital; Shanghai China

24. Department of Infectious Diseases; Xiangya Hospital, Central South University; Changsha China

25. Liver Research Center, Beijing Friendship Hospital; Capital Medical University; Beijing China

Funder

National Science and Technology Major Project of China

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jgh.12835/fullpdf

Reference20 articles.

1. EASL clinical practice guidelines: management of chronic hepatitis B virus infection;European Association for the Study of the Liver;J. Hepatol.,2012

2. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses;Woo;Gastroenterology,2010

3. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis;Wong;Hepatology,2013

4. Lamivudine for patients with chronic hepatitis B and advanced liver disease;Liaw;N. Engl. J. Med.,2004

5. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years;Hadziyannis;Gastroenterology,2006

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Host sex disparity and viral genotype dependence of the glycosylation level of small Hepatitis B surface protein in patients with HBeAg-positive chronic Hepatitis B;Virology Journal;2023-07-19

2. TRIM26 inhibits hepatitis B virus replication by promoting HBx degradation and TRIM26 genetic polymorphism predicts PegIFNα treatment response of HBeAg‐positive chronic hepatitis B Patients;Alimentary Pharmacology & Therapeutics;2022-07-24

3. CD55 Variant Associated with Pegylated-interferon α Therapy Response in HBeAg-positive Chronic Hepatitis B Patients;Journal of Clinical and Translational Hepatology;2022-06-01

4. A Missense Variant in Granulysin is Associated with the Efficacy of Pegylated-Interferon-Alpha Therapy in Chinese Patients with HBeAg-Positive Chronic Hepatitis B;Pharmacogenomics and Personalized Medicine;2021-11

5. Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients With Chronic Hepatitis B Virus Infection: Systematic Review and Meta-analysis;Clinical Gastroenterology and Hepatology;2021-03